Gilead Sciences (GILD) Stock Forecast & Price Target

Compare

13,746 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GILD Analyst Ratings

Strong Buy

16 Buy

3 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$135.43

▲(11.69% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $135.43 with a high forecast of $150.00 and a low forecast of $100.00. The average price target represents a 11.69% change from the last price of $121.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"$88","151":"$151","103.75":"$103.8","119.5":"$119.5","135.25":"$135.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$150.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$135.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,103.75,119.5,135.25,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122.74,124.83692307692307,126.93384615384615,129.03076923076924,131.1276923076923,133.2246153846154,135.32153846153847,137.41846153846154,139.51538461538462,141.6123076923077,143.70923076923077,145.80615384615385,147.90307692307692,{"y":150,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122.74,123.71615384615384,124.6923076923077,125.66846153846154,126.64461538461538,127.62076923076923,128.59692307692308,129.5730769230769,130.54923076923077,131.5253846153846,132.50153846153847,133.4776923076923,134.45384615384617,{"y":135.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122.74,120.99076923076923,119.24153846153845,117.49230769230769,115.74307692307691,113.99384615384615,112.24461538461539,110.49538461538461,108.74615384615385,106.99692307692308,105.2476923076923,103.49846153846154,101.74923076923076,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$150.00

Average Price Target$135.43

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

Buy

―

Reiterated

01/13/26

Analysts Are Bullish on Top Healthcare Stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX)

Terence Flynn

Morgan Stanley

$151→$150

Buy

23.70%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Apellis Pharmaceuticals (NASDAQ: APLS) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Courtney Breen

Bernstein

$135

Buy

11.33%

Upside

Reiterated

01/13/26

Bernstein Remains a Buy on Gilead Sciences (GILD)

Chris Schott

J.P. Morgan

Buy

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and GRAIL Inc (NASDAQ: GRAL)

Tazeen Ahmad

Bank of America Securities

Buy

―

Reiterated

01/13/26

Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Progyny (PGNY)

Tyler Van Buren

TD Cowen

$115→$125

Buy

3.08%

Upside

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (NASDAQ: AVAH) and Gilead Sciences (NASDAQ: GILD)

Evan Seigerman

BMO Capital

$135

Buy

11.33%

Upside

Reiterated

01/12/26

Gilead Sciences: Durable HIV Leadership and De‑Risking Oncology Pipeline Support Compelling Buy-Rated Risk‑Reward

Geoff Meacham

Citi

$140

Buy

15.45%

Upside

Reiterated

01/12/26

Gilead Sciences (GILD) Receives a Buy from Citi

Louise Chen

Scotiabank

$140

Buy

15.45%

Upside

Reiterated

01/12/26

Brian Abrahams

RBC Capital

$105→$100

Hold

-17.53%

Downside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Biodesix (NASDAQ: BDSX), Gilead Sciences (NASDAQ: GILD) and Agios Pharma (NASDAQ: AGIO)

Michael Yee

UBS

$112→$145

Buy

19.58%

Upside

Upgraded

01/07/26

Gilead Sciences: PrEP-Led Growth, Easing HIV Overhangs, and Pipeline Upside Support Buy Rating and 2027 Re-Rating Target

Joseph Stringer

Needham

$140

Buy

15.45%

Upside

Reiterated

12/15/25

Gilead Sciences: Strategic Expansion in HIV Treatment Bolsters Buy Rating

Mohit Bansal

Wells Fargo

$145→$150

Buy

23.70%

Upside

Reiterated

12/10/25

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

Morten Herholdt

HSBC

$110→$133

Hold

9.68%

Upside

Reiterated

12/10/25

Gilead price target raised to $133 from $110 at HSBCGilead price target raised to $133 from $110 at HSBC

Carter Gould

Cantor Fitzgerald

$135

Buy

11.33%

Upside

Reiterated

12/07/25

Cantor Fitzgerald Remains a Buy on Gilead Sciences (GILD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

Buy

―

Reiterated

01/13/26

Analysts Are Bullish on Top Healthcare Stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX)

Terence Flynn

Morgan Stanley

$151→$150

Buy

23.70%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Apellis Pharmaceuticals (NASDAQ: APLS) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Courtney Breen

Bernstein

$135

Buy

11.33%

Upside

Reiterated

01/13/26

Bernstein Remains a Buy on Gilead Sciences (GILD)

Chris Schott

J.P. Morgan

Buy

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and GRAIL Inc (NASDAQ: GRAL)

Tazeen Ahmad

Bank of America Securities

Buy

―

Reiterated

01/13/26

Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Progyny (PGNY)

Tyler Van Buren

TD Cowen

$115→$125

Buy

3.08%

Upside

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (NASDAQ: AVAH) and Gilead Sciences (NASDAQ: GILD)

Evan Seigerman

BMO Capital

$135

Buy

11.33%

Upside

Reiterated

01/12/26

Gilead Sciences: Durable HIV Leadership and De‑Risking Oncology Pipeline Support Compelling Buy-Rated Risk‑Reward

Geoff Meacham

Citi

$140

Buy

15.45%

Upside

Reiterated

01/12/26

Gilead Sciences (GILD) Receives a Buy from Citi

Louise Chen

Scotiabank

$140

Buy

15.45%

Upside

Reiterated

01/12/26

Brian Abrahams

RBC Capital

$105→$100

Hold

-17.53%

Downside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Biodesix (NASDAQ: BDSX), Gilead Sciences (NASDAQ: GILD) and Agios Pharma (NASDAQ: AGIO)

Michael Yee

UBS

$112→$145

Buy

19.58%

Upside

Upgraded

01/07/26

Gilead Sciences: PrEP-Led Growth, Easing HIV Overhangs, and Pipeline Upside Support Buy Rating and 2027 Re-Rating Target

Joseph Stringer

Needham

$140

Buy

15.45%

Upside

Reiterated

12/15/25

Gilead Sciences: Strategic Expansion in HIV Treatment Bolsters Buy Rating

Mohit Bansal

Wells Fargo

$145→$150

Buy

23.70%

Upside

Reiterated

12/10/25

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

Morten Herholdt

HSBC

$110→$133

Hold

9.68%

Upside

Reiterated

12/10/25

Gilead price target raised to $133 from $110 at HSBCGilead price target raised to $133 from $110 at HSBC

Carter Gould

Cantor Fitzgerald

$135

Buy

11.33%

Upside

Reiterated

12/07/25

Cantor Fitzgerald Remains a Buy on Gilead Sciences (GILD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months

xxx

Success Rate

24/31 ratings generated profit

Average Return

+5.89%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.42% of your transactions generating a profit, with an average return of +5.89% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

28/31 ratings generated profit

Average Return

+26.88%

reiterated a buy rating 3 months ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 90.32% of your transactions generating a profit, with an average return of +26.88% per trade.

2 Years

xxx

Success Rate

20/20 ratings generated profit

Average Return

+37.84%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +37.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GILD has received 31 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 135.43.

Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is $1.85 with a range of $1.60 to $2.01. The previous quarter’s EPS was $2.47. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $7.68B with a range of $6.95B to $8.20B. The previous quarter’s sales results were $7.78B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 135.43.

What is GILD’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 11.69% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GILD a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.

What is Gilead Sciences’s price target?

The average price target for Gilead Sciences is 135.43. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $150.00 ,the lowest forecast is $100.00. The average price target represents 11.69% Increase from the current price of $121.26.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of GILD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Gilead Sciences (GILD) Stock Forecast & Price Target

GILD Analyst Ratings

GILD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

GILD Analyst Recommendation Trends

GILD Financial Forecast

GILD Earnings Forecast

GILD Sales Forecast

GILD Stock Forecast FAQ

Detailed List of Analyst Forecasts